Market revenue in 2024 | USD 32.2 million |
Market revenue in 2030 | USD 17.4 million |
Growth rate | -10.2% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 54.35% in 2024. Horizon Databook has segmented the Thailand anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
In Thailand, the anti-VEGF therapeutics market is emerging as healthcare access improves, driven by urbanization and a growing middle class with higher health awareness. The incidence of AMD and diabetic retinopathy has increased alongside diabetes prevalence, intensifying demand for specialized ophthalmic treatments.
A 2021 study published by the NCBI found that the overall prevalence of diabetic retinopathy (DR) among Thai patients with type 2 diabetes (T2D) ranged from 5.0% to 6.9%. This prevalence is relatively low when compared to rates observed in other countries, including Italy, the United States, and China, as well as the global prevalence of DR among T2D patients.
While marketleading brands such as Lucentis and Avastin are prominent, the Thai government’s healthcare reforms and focus on expanding rural healthcare access are opening doors for biosimilars. Partnerships between global and regional firms are common, aiming to address gaps in availability and affordability.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Thailand anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account